

# COVID-19 Impact on Global Targeted Drugs for Multiple Myeloma Market Size, Status and Forecast 2020-2026

<https://marketpublishers.com/r/C6F41575829DEN.html>

Date: July 2020

Pages: 155

Price: US\$ 3,900.00 (Single User License)

ID: C6F41575829DEN

## Abstracts

This report focuses on the global Targeted Drugs for Multiple Myeloma status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Targeted Drugs for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Celgene

Exova

Natco Pharma

Intas Pharmaceuticals

Indiabulls Pharmaceutical

Cipla

Glenmark Pharmaceuticals

Dr Reddy's Laboratories

Qilu Pharmaceutical

Chia Tai-Tianqing

Hanson Pharm

Meidakang Huakang Pharmaceutical

Shandong Kongfu Pharmaceutical

J&J

Takeda

Amgen

Bristol Myers Squibb

Abbvie

Seattle Genetics

Karyopharm Therapeutics

PDL BioPharma

Roche

Sumitomo

Merck

Biogen

Schering-Plough

Glaxo

Chiron

Market segment by Type, the product can be split into

Immunomodulator

Proteasome Inhibitors

Histone Deacetylase Inhibitors (HDACI)

Monoclonal Antibody

Other

Market segment by Application, split into

Hospital

Drug Center

Clinic

Other

Market segment by Regions/Countries, this report covers

North America

Europe

China

Japan

Southeast Asia

India

Central & South America

The study objectives of this report are:

To analyze global Targeted Drugs for Multiple Myeloma status, future forecast, growth opportunity, key market and key players.

To present the Targeted Drugs for Multiple Myeloma development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

To strategically profile the key players and comprehensively analyze their development plan and strategies.

To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Targeted Drugs for Multiple Myeloma are as follows:

History Year: 2015-2019

Base Year: 2019

Estimated Year: 2020

Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

## Contents

### 1 REPORT OVERVIEW

1.1 Study Scope

1.2 Key Market Segments

1.3 Players Covered: Ranking by Targeted Drugs for Multiple Myeloma Revenue

1.4 Market Analysis by Type

1.4.1 Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type:  
2020 VS 2026

1.4.2 Immunomodulator

1.4.3 Proteasome Inhibitors

1.4.4 Histone Deacetylase Inhibitors (HDACI)

1.4.5 Monoclonal Antibody

1.4.6 Other

1.5 Market by Application

1.5.1 Global Targeted Drugs for Multiple Myeloma Market Share by Application: 2020  
VS 2026

1.5.2 Hospital

1.5.3 Drug Center

1.5.4 Clinic

1.5.5 Other

1.6 Coronavirus Disease 2019 (Covid-19): Targeted Drugs for Multiple Myeloma  
Industry Impact

1.6.1 How the Covid-19 is Affecting the Targeted Drugs for Multiple Myeloma Industry

1.6.1.1 Targeted Drugs for Multiple Myeloma Business Impact Assessment -  
Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19's Impact On Crude Oil and Refined Products

1.6.2 Market Trends and Targeted Drugs for Multiple Myeloma Potential Opportunities  
in the COVID-19 Landscape

1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Targeted Drugs for Multiple Myeloma Players to Combat  
Covid-19 Impact

1.7 Study Objectives

1.8 Years Considered

### 2 GLOBAL GROWTH TRENDS BY REGIONS

- 2.1 Targeted Drugs for Multiple Myeloma Market Perspective (2015-2026)
- 2.2 Targeted Drugs for Multiple Myeloma Growth Trends by Regions
  - 2.2.1 Targeted Drugs for Multiple Myeloma Market Size by Regions: 2015 VS 2020 VS 2026
  - 2.2.2 Targeted Drugs for Multiple Myeloma Historic Market Share by Regions (2015-2020)
  - 2.2.3 Targeted Drugs for Multiple Myeloma Forecasted Market Size by Regions (2021-2026)
- 2.3 Industry Trends and Growth Strategy
  - 2.3.1 Market Top Trends
  - 2.3.2 Market Drivers
  - 2.3.3 Market Challenges
  - 2.3.4 Porter's Five Forces Analysis
  - 2.3.5 Targeted Drugs for Multiple Myeloma Market Growth Strategy
  - 2.3.6 Primary Interviews with Key Targeted Drugs for Multiple Myeloma Players (Opinion Leaders)

### **3 COMPETITION LANDSCAPE BY KEY PLAYERS**

- 3.1 Global Top Targeted Drugs for Multiple Myeloma Players by Market Size
  - 3.1.1 Global Top Targeted Drugs for Multiple Myeloma Players by Revenue (2015-2020)
  - 3.1.2 Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Players (2015-2020)
  - 3.1.3 Global Targeted Drugs for Multiple Myeloma Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
- 3.2 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio
  - 3.2.1 Global Targeted Drugs for Multiple Myeloma Market Concentration Ratio (CR5 and HHI)
  - 3.2.2 Global Top 10 and Top 5 Companies by Targeted Drugs for Multiple Myeloma Revenue in 2019
- 3.3 Targeted Drugs for Multiple Myeloma Key Players Head office and Area Served
- 3.4 Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
- 3.5 Date of Enter into Targeted Drugs for Multiple Myeloma Market
- 3.6 Mergers & Acquisitions, Expansion Plans

### **4 BREAKDOWN DATA BY TYPE (2015-2026)**

4.1 Global Targeted Drugs for Multiple Myeloma Historic Market Size by Type (2015-2020)

4.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Type (2021-2026)

## **5 TARGETED DRUGS FOR MULTIPLE MYELOMA BREAKDOWN DATA BY APPLICATION (2015-2026)**

5.1 Global Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

5.2 Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Application (2021-2026)

## **6 NORTH AMERICA**

6.1 North America Targeted Drugs for Multiple Myeloma Market Size (2015-2020)

6.2 Targeted Drugs for Multiple Myeloma Key Players in North America (2019-2020)

6.3 North America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)

6.4 North America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

## **7 EUROPE**

7.1 Europe Targeted Drugs for Multiple Myeloma Market Size (2015-2020)

7.2 Targeted Drugs for Multiple Myeloma Key Players in Europe (2019-2020)

7.3 Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)

7.4 Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

## **8 CHINA**

8.1 China Targeted Drugs for Multiple Myeloma Market Size (2015-2020)

8.2 Targeted Drugs for Multiple Myeloma Key Players in China (2019-2020)

8.3 China Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)

8.4 China Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

## **9 JAPAN**

- 9.1 Japan Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
- 9.2 Targeted Drugs for Multiple Myeloma Key Players in Japan (2019-2020)
- 9.3 Japan Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
- 9.4 Japan Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

## **10 SOUTHEAST ASIA**

- 10.1 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
- 10.2 Targeted Drugs for Multiple Myeloma Key Players in Southeast Asia (2019-2020)
- 10.3 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
- 10.4 Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

## **11 INDIA**

- 11.1 India Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
- 11.2 Targeted Drugs for Multiple Myeloma Key Players in India (2019-2020)
- 11.3 India Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
- 11.4 India Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

## **12 CENTRAL & SOUTH AMERICA**

- 12.1 Central & South America Targeted Drugs for Multiple Myeloma Market Size (2015-2020)
- 12.2 Targeted Drugs for Multiple Myeloma Key Players in Central & South America (2019-2020)
- 12.3 Central & South America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020)
- 12.4 Central & South America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020)

## **13 KEY PLAYERS PROFILES**

- 13.1 Celgene
  - 13.1.1 Celgene Company Details
  - 13.1.2 Celgene Business Overview and Its Total Revenue
  - 13.1.3 Celgene Targeted Drugs for Multiple Myeloma Introduction
  - 13.1.4 Celgene Revenue in Targeted Drugs for Multiple Myeloma Business



(2015-2020))

13.1.5 Celgene Recent Development

13.2 Exova

13.2.1 Exova Company Details

13.2.2 Exova Business Overview and Its Total Revenue

13.2.3 Exova Targeted Drugs for Multiple Myeloma Introduction

13.2.4 Exova Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

13.2.5 Exova Recent Development

13.3 Natco Pharma

13.3.1 Natco Pharma Company Details

13.3.2 Natco Pharma Business Overview and Its Total Revenue

13.3.3 Natco Pharma Targeted Drugs for Multiple Myeloma Introduction

13.3.4 Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business

(2015-2020)

13.3.5 Natco Pharma Recent Development

13.4 Intas Pharmaceuticals

13.4.1 Intas Pharmaceuticals Company Details

13.4.2 Intas Pharmaceuticals Business Overview and Its Total Revenue

13.4.3 Intas Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction

13.4.4 Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

13.4.5 Intas Pharmaceuticals Recent Development

13.5 Indiabulls Pharmaceutical

13.5.1 Indiabulls Pharmaceutical Company Details

13.5.2 Indiabulls Pharmaceutical Business Overview and Its Total Revenue

13.5.3 Indiabulls Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction

13.5.4 Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

13.5.5 Indiabulls Pharmaceutical Recent Development

13.6 Cipla

13.6.1 Cipla Company Details

13.6.2 Cipla Business Overview and Its Total Revenue

13.6.3 Cipla Targeted Drugs for Multiple Myeloma Introduction

13.6.4 Cipla Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

13.6.5 Cipla Recent Development

13.7 Glenmark Pharmaceuticals

13.7.1 Glenmark Pharmaceuticals Company Details

13.7.2 Glenmark Pharmaceuticals Business Overview and Its Total Revenue

13.7.3 Glenmark Pharmaceuticals Targeted Drugs for Multiple Myeloma Introduction

13.7.4 Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

13.7.5 Glenmark Pharmaceuticals Recent Development

13.8 Dr Reddy's Laboratories

13.8.1 Dr Reddy's Laboratories Company Details

13.8.2 Dr Reddy's Laboratories Business Overview and Its Total Revenue

13.8.3 Dr Reddy's Laboratories Targeted Drugs for Multiple Myeloma Introduction

13.8.4 Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

13.8.5 Dr Reddy's Laboratories Recent Development

13.9 Qilu Pharmaceutical

13.9.1 Qilu Pharmaceutical Company Details

13.9.2 Qilu Pharmaceutical Business Overview and Its Total Revenue

13.9.3 Qilu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction

13.9.4 Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

13.9.5 Qilu Pharmaceutical Recent Development

13.10 Chia Tai-Tianqing

13.10.1 Chia Tai-Tianqing Company Details

13.10.2 Chia Tai-Tianqing Business Overview and Its Total Revenue

13.10.3 Chia Tai-Tianqing Targeted Drugs for Multiple Myeloma Introduction

13.10.4 Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

13.10.5 Chia Tai-Tianqing Recent Development

13.11 Hanson Pharm

10.11.1 Hanson Pharm Company Details

10.11.2 Hanson Pharm Business Overview and Its Total Revenue

10.11.3 Hanson Pharm Targeted Drugs for Multiple Myeloma Introduction

10.11.4 Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

10.11.5 Hanson Pharm Recent Development

13.12 Meidakang Huakang Pharmaceutical

10.12.1 Meidakang Huakang Pharmaceutical Company Details

10.12.2 Meidakang Huakang Pharmaceutical Business Overview and Its Total Revenue

10.12.3 Meidakang Huakang Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction

10.12.4 Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

- 10.12.5 Meidakang Huakang Pharmaceutical Recent Development
- 13.13 Shandong Kongfu Pharmaceutical
  - 10.13.1 Shandong Kongfu Pharmaceutical Company Details
  - 10.13.2 Shandong Kongfu Pharmaceutical Business Overview and Its Total Revenue
  - 10.13.3 Shandong Kongfu Pharmaceutical Targeted Drugs for Multiple Myeloma Introduction
  - 10.13.4 Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  - 10.13.5 Shandong Kongfu Pharmaceutical Recent Development
- 13.14 J&J
  - 10.14.1 J&J Company Details
  - 10.14.2 J&J Business Overview and Its Total Revenue
  - 10.14.3 J&J Targeted Drugs for Multiple Myeloma Introduction
  - 10.14.4 J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  - 10.14.5 J&J Recent Development
- 13.15 Takeda
  - 10.15.1 Takeda Company Details
  - 10.15.2 Takeda Business Overview and Its Total Revenue
  - 10.15.3 Takeda Targeted Drugs for Multiple Myeloma Introduction
  - 10.15.4 Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  - 10.15.5 Takeda Recent Development
- 13.16 Amgen
  - 10.16.1 Amgen Company Details
  - 10.16.2 Amgen Business Overview and Its Total Revenue
  - 10.16.3 Amgen Targeted Drugs for Multiple Myeloma Introduction
  - 10.16.4 Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  - 10.16.5 Amgen Recent Development
- 13.17 Bristol Myers Squibb
  - 10.17.1 Bristol Myers Squibb Company Details
  - 10.17.2 Bristol Myers Squibb Business Overview and Its Total Revenue
  - 10.17.3 Bristol Myers Squibb Targeted Drugs for Multiple Myeloma Introduction
  - 10.17.4 Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  - 10.17.5 Bristol Myers Squibb Recent Development
- 13.18 Abbvie
  - 10.18.1 Abbvie Company Details
  - 10.18.2 Abbvie Business Overview and Its Total Revenue

- 10.18.3 Abbvie Targeted Drugs for Multiple Myeloma Introduction
- 10.18.4 Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
- 10.18.5 Abbvie Recent Development
- 13.19 Seattle Genetics
  - 10.19.1 Seattle Genetics Company Details
  - 10.19.2 Seattle Genetics Business Overview and Its Total Revenue
  - 10.19.3 Seattle Genetics Targeted Drugs for Multiple Myeloma Introduction
  - 10.19.4 Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  - 10.19.5 Seattle Genetics Recent Development
- 13.20 Karyopharm Therapeutics
  - 10.20.1 Karyopharm Therapeutics Company Details
  - 10.20.2 Karyopharm Therapeutics Business Overview and Its Total Revenue
  - 10.20.3 Karyopharm Therapeutics Targeted Drugs for Multiple Myeloma Introduction
  - 10.20.4 Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  - 10.20.5 Karyopharm Therapeutics Recent Development
- 13.21 PDL BioPharma
  - 10.21.1 PDL BioPharma Company Details
  - 10.21.2 PDL BioPharma Business Overview and Its Total Revenue
  - 10.21.3 PDL BioPharma Targeted Drugs for Multiple Myeloma Introduction
  - 10.21.4 PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  - 10.21.5 PDL BioPharma Recent Development
- 13.22 Roche
  - 10.22.1 Roche Company Details
  - 10.22.2 Roche Business Overview and Its Total Revenue
  - 10.22.3 Roche Targeted Drugs for Multiple Myeloma Introduction
  - 10.22.4 Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  - 10.22.5 Roche Recent Development
- 13.23 Sumitomo
  - 10.23.1 Sumitomo Company Details
  - 10.23.2 Sumitomo Business Overview and Its Total Revenue
  - 10.23.3 Sumitomo Targeted Drugs for Multiple Myeloma Introduction
  - 10.23.4 Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)
  - 10.23.5 Sumitomo Recent Development

### 13.24 Merck

10.24.1 Merck Company Details

10.24.2 Merck Business Overview and Its Total Revenue

10.24.3 Merck Targeted Drugs for Multiple Myeloma Introduction

10.24.4 Merck Revenue in Targeted Drugs for Multiple Myeloma Business  
(2015-2020)

10.24.5 Merck Recent Development

### 13.25 Biogen

10.25.1 Biogen Company Details

10.25.2 Biogen Business Overview and Its Total Revenue

10.25.3 Biogen Targeted Drugs for Multiple Myeloma Introduction

10.25.4 Biogen Revenue in Targeted Drugs for Multiple Myeloma Business  
(2015-2020)

10.25.5 Biogen Recent Development

### 13.26 Schering-Plough

10.26.1 Schering-Plough Company Details

10.26.2 Schering-Plough Business Overview and Its Total Revenue

10.26.3 Schering-Plough Targeted Drugs for Multiple Myeloma Introduction

10.26.4 Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business  
(2015-2020)

10.26.5 Schering-Plough Recent Development

### 13.27 Glaxo

10.27.1 Glaxo Company Details

10.27.2 Glaxo Business Overview and Its Total Revenue

10.27.3 Glaxo Targeted Drugs for Multiple Myeloma Introduction

10.27.4 Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

10.27.5 Glaxo Recent Development

### 13.28 Chiron

10.28.1 Chiron Company Details

10.28.2 Chiron Business Overview and Its Total Revenue

10.28.3 Chiron Targeted Drugs for Multiple Myeloma Introduction

10.28.4 Chiron Revenue in Targeted Drugs for Multiple Myeloma Business  
(2015-2020)

10.28.5 Chiron Recent Development

## **14 ANALYST'S VIEWPOINTS/CONCLUSIONS**

## **15 APPENDIX**

## 15.1 Research Methodology

### 15.1.1 Methodology/Research Approach

### 15.1.2 Data Source

## 15.2 Disclaimer

## 15.3 Author Details

## List Of Tables

### LIST OF TABLES

Table 1. Targeted Drugs for Multiple Myeloma Key Market Segments

Table 2. Key Players Covered: Ranking by Targeted Drugs for Multiple Myeloma Revenue

Table 3. Ranking of Global Top Targeted Drugs for Multiple Myeloma Manufacturers by Revenue (US\$ Million) in 2019

Table 4. Global Targeted Drugs for Multiple Myeloma Market Size Growth Rate by Type (US\$ Million): 2020 VS 2026

Table 5. Key Players of Immunomodulator

Table 6. Key Players of Proteasome Inhibitors

Table 7. Key Players of Histone Deacetylase Inhibitors (HDACI)

Table 8. Key Players of Monoclonal Antibody

Table 9. Key Players of Other

Table 10. COVID-19 Impact Global Market: (Four Targeted Drugs for Multiple Myeloma Market Size Forecast Scenarios)

Table 11. Opportunities and Trends for Targeted Drugs for Multiple Myeloma Players in the COVID-19 Landscape

Table 12. Present Opportunities in China & Elsewhere Due to the Coronavirus Crisis

Table 13. Key Regions/Countries Measures against Covid-19 Impact

Table 14. Proposal for Targeted Drugs for Multiple Myeloma Players to Combat Covid-19 Impact

Table 15. Global Targeted Drugs for Multiple Myeloma Market Size Growth by Application (US\$ Million): 2020 VS 2026

Table 16. Global Targeted Drugs for Multiple Myeloma Market Size by Regions (US\$ Million): 2020 VS 2026

Table 17. Global Targeted Drugs for Multiple Myeloma Market Size by Regions (2015-2020) (US\$ Million)

Table 18. Global Targeted Drugs for Multiple Myeloma Market Share by Regions (2015-2020)

Table 19. Global Targeted Drugs for Multiple Myeloma Forecasted Market Size by Regions (2021-2026) (US\$ Million)

Table 20. Global Targeted Drugs for Multiple Myeloma Market Share by Regions (2021-2026)

Table 21. Market Top Trends

Table 22. Key Drivers: Impact Analysis

Table 23. Key Challenges

- Table 24. Targeted Drugs for Multiple Myeloma Market Growth Strategy
- Table 25. Main Points Interviewed from Key Targeted Drugs for Multiple Myeloma Players
- Table 26. Global Targeted Drugs for Multiple Myeloma Revenue by Players (2015-2020) (Million US\$)
- Table 27. Global Targeted Drugs for Multiple Myeloma Market Share by Players (2015-2020)
- Table 28. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2019)
- Table 29. Global Targeted Drugs for Multiple Myeloma by Players Market Concentration Ratio (CR5 and HHI)
- Table 30. Key Players Headquarters and Area Served
- Table 31. Key Players Targeted Drugs for Multiple Myeloma Product Solution and Service
- Table 32. Date of Enter into Targeted Drugs for Multiple Myeloma Market
- Table 33. Mergers & Acquisitions, Expansion Plans
- Table 34. Global Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)
- Table 35. Global Targeted Drugs for Multiple Myeloma Market Size Share by Type (2015-2020)
- Table 36. Global Targeted Drugs for Multiple Myeloma Revenue Market Share by Type (2021-2026)
- Table 37. Global Targeted Drugs for Multiple Myeloma Market Size Share by Application (2015-2020)
- Table 38. Global Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)
- Table 39. Global Targeted Drugs for Multiple Myeloma Market Size Share by Application (2021-2026)
- Table 40. North America Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US\$)
- Table 41. North America Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)
- Table 42. North America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)
- Table 43. North America Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)
- Table 44. North America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)



Table 45. North America Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)

Table 46. Europe Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 47. Europe Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)

Table 48. Europe Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 49. Europe Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)

Table 50. Europe Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 51. Europe Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)

Table 52. China Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 53. China Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)

Table 54. China Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 55. China Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)

Table 56. China Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 57. China Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)

Table 58. Japan Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 59. Japan Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)

Table 60. Japan Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 61. Japan Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)

Table 62. Japan Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 63. Japan Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)

Table 64. Southeast Asia Key Players Targeted Drugs for Multiple Myeloma Revenue

(2019-2020) (Million US\$)

Table 65. Southeast Asia Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)

Table 66. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 67. Southeast Asia Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)

Table 68. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 69. Southeast Asia Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)

Table 70. India Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 71. India Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)

Table 72. India Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 73. India Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)

Table 74. India Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 75. India Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)

Table 76. Central & South America Key Players Targeted Drugs for Multiple Myeloma Revenue (2019-2020) (Million US\$)

Table 77. Central & South America Key Players Targeted Drugs for Multiple Myeloma Market Share (2019-2020)

Table 78. Central & South America Targeted Drugs for Multiple Myeloma Market Size by Type (2015-2020) (Million US\$)

Table 79. Central & South America Targeted Drugs for Multiple Myeloma Market Share by Type (2015-2020)

Table 80. Central & South America Targeted Drugs for Multiple Myeloma Market Size by Application (2015-2020) (Million US\$)

Table 81. Central & South America Targeted Drugs for Multiple Myeloma Market Share by Application (2015-2020)

Table 82. Celgene Company Details

Table 83. Celgene Business Overview

Table 84. Celgene Product

Table 85. Celgene Revenue in Targeted Drugs for Multiple Myeloma Business

(2015-2020) (Million US\$)

Table 86. Celgene Recent Development

Table 87. Exova Company Details

Table 88. Exova Business Overview

Table 89. Exova Product

Table 90. Exova Revenue in Targeted Drugs for Multiple Myeloma Business

(2015-2020) (Million US\$)

Table 91. Exova Recent Development

Table 92. Natco Pharma Company Details

Table 93. Natco Pharma Business Overview

Table 94. Natco Pharma Product

Table 95. Natco Pharma Revenue in Targeted Drugs for Multiple Myeloma Business

(2015-2020) (Million US\$)

Table 96. Natco Pharma Recent Development

Table 97. Intas Pharmaceuticals Company Details

Table 98. Intas Pharmaceuticals Business Overview

Table 99. Intas Pharmaceuticals Product

Table 100. Intas Pharmaceuticals Revenue in Targeted Drugs for Multiple Myeloma

Business (2015-2020) (Million US\$)

Table 101. Intas Pharmaceuticals Recent Development

Table 102. Indiabulls Pharmaceutical Company Details

Table 103. Indiabulls Pharmaceutical Business Overview

Table 104. Indiabulls Pharmaceutical Product

Table 105. Indiabulls Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma

Business (2015-2020) (Million US\$)

Table 106. Indiabulls Pharmaceutical Recent Development

Table 107. Cipla Company Details

Table 108. Cipla Business Overview

Table 109. Cipla Product

Table 110. Cipla Revenue in Targeted Drugs for Multiple Myeloma Business

(2015-2020) (Million US\$)

Table 111. Cipla Recent Development

Table 112. Glenmark Pharmaceuticals Company Details

Table 113. Glenmark Pharmaceuticals Business Overview

Table 114. Glenmark Pharmaceuticals Product

Table 115. Glenmark Pharmaceuticals Revenue in Targeted Drugs for Multiple

Myeloma Business (2015-2020) (Million US\$)

Table 116. Glenmark Pharmaceuticals Recent Development

Table 117. Dr Reddy's Laboratories Business Overview

- Table 118. Dr Reddy's Laboratories Product
- Table 119. Dr Reddy's Laboratories Company Details
- Table 120. Dr Reddy's Laboratories Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 121. Dr Reddy's Laboratories Recent Development
- Table 122. Qilu Pharmaceutical Company Details
- Table 123. Qilu Pharmaceutical Business Overview
- Table 124. Qilu Pharmaceutical Product
- Table 125. Qilu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 126. Qilu Pharmaceutical Recent Development
- Table 127. Chia Tai-Tianqing Company Details
- Table 128. Chia Tai-Tianqing Business Overview
- Table 129. Chia Tai-Tianqing Product
- Table 130. Chia Tai-Tianqing Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 131. Chia Tai-Tianqing Recent Development
- Table 132. Hanson Pharm Company Details
- Table 133. Hanson Pharm Business Overview
- Table 134. Hanson Pharm Product
- Table 135. Hanson Pharm Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 136. Hanson Pharm Recent Development
- Table 137. Meidakang Huakang Pharmaceutical Company Details
- Table 138. Meidakang Huakang Pharmaceutical Business Overview
- Table 139. Meidakang Huakang Pharmaceutical Product
- Table 140. Meidakang Huakang Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 141. Meidakang Huakang Pharmaceutical Recent Development
- Table 142. Shandong Kongfu Pharmaceutical Company Details
- Table 143. Shandong Kongfu Pharmaceutical Business Overview
- Table 144. Shandong Kongfu Pharmaceutical Product
- Table 145. Shandong Kongfu Pharmaceutical Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 146. Shandong Kongfu Pharmaceutical Recent Development
- Table 147. J&J Company Details
- Table 148. J&J Business Overview
- Table 149. J&J Product
- Table 150. J&J Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020)

(Million US\$)

Table 151. J&J Recent Development

Table 152. Takeda Company Details

Table 153. Takeda Business Overview

Table 154. Takeda Product

Table 155. Takeda Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 156. Takeda Recent Development

Table 157. Amgen Company Details

Table 158. Amgen Business Overview

Table 159. Amgen Product

Table 160. Amgen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 161. Amgen Recent Development

Table 162. Bristol Myers Squibb Company Details

Table 163. Bristol Myers Squibb Business Overview

Table 164. Bristol Myers Squibb Product

Table 165. Bristol Myers Squibb Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 166. Bristol Myers Squibb Recent Development

Table 167. Abbvie Company Details

Table 168. Abbvie Business Overview

Table 169. Abbvie Product

Table 170. Abbvie Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 171. Abbvie Recent Development

Table 172. Seattle Genetics Company Details

Table 173. Seattle Genetics Business Overview

Table 174. Seattle Genetics Product

Table 175. Seattle Genetics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 176. Seattle Genetics Recent Development

Table 177. Karyopharm Therapeutics Company Details

Table 178. Karyopharm Therapeutics Business Overview

Table 179. Karyopharm Therapeutics Product

Table 180. Karyopharm Therapeutics Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)

Table 181. Karyopharm Therapeutics Recent Development

Table 182. PDL BioPharma Company Details

- Table 183. PDL BioPharma Business Overview
- Table 184. PDL BioPharma Product
- Table 185. PDL BioPharma Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 186. PDL BioPharma Recent Development
- Table 187. Roche Company Details
- Table 188. Roche Business Overview
- Table 189. Roche Product
- Table 190. Roche Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 191. Roche Recent Development
- Table 192. Sumitomo Company Details
- Table 193. Sumitomo Business Overview
- Table 194. Sumitomo Product
- Table 195. Sumitomo Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 196. Sumitomo Recent Development
- Table 197. Merck Company Details
- Table 198. Merck Business Overview
- Table 199. Merck Product
- Table 200. Merck Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 201. Merck Recent Development
- Table 202. Biogen Company Details
- Table 203. Biogen Business Overview
- Table 204. Biogen Product
- Table 205. Biogen Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 206. Biogen Recent Development
- Table 207. Schering-Plough Company Details
- Table 208. Schering-Plough Business Overview
- Table 209. Schering-Plough Product
- Table 210. Schering-Plough Revenue in Targeted Drugs for Multiple Myeloma Business (2015-2020) (Million US\$)
- Table 211. Schering-Plough Recent Development
- Table 212. Glaxo Company Details
- Table 213. Glaxo Business Overview
- Table 214. Glaxo Product
- Table 215. Glaxo Revenue in Targeted Drugs for Multiple Myeloma Business

(2015-2020) (Million US\$)

Table 216. Glaxo Recent Development

Table 217. Chiron Company Details

Table 218. Chiron Business Overview

Table 219. Chiron Product

Table 220. Chiron Revenue in Targeted Drugs for Multiple Myeloma Business

(2015-2020) (Million US\$)

Table 221. Chiron Recent Development

Table 222. Research Programs/Design for This Report

Table 223. Key Data Information from Secondary Sources

Table 224. Key Data Information from Primary Sources

## List Of Figures

### LIST OF FIGURES

- Figure 1. Global Targeted Drugs for Multiple Myeloma Market Share by Type: 2020 VS 2026
- Figure 2. Immunomodulator Features
- Figure 3. Proteasome Inhibitors Features
- Figure 4. Histone Deacetylase Inhibitors (HDACI) Features
- Figure 5. Monoclonal Antibody Features
- Figure 6. Other Features
- Figure 7. Global Targeted Drugs for Multiple Myeloma Market Share by Application: 2020 VS 2026
- Figure 8. Hospital Case Studies
- Figure 9. Drug Center Case Studies
- Figure 10. Clinic Case Studies
- Figure 11. Other Case Studies
- Figure 12. Targeted Drugs for Multiple Myeloma Report Years Considered
- Figure 13. Global Targeted Drugs for Multiple Myeloma Market Size YoY Growth 2015-2026 (US\$ Million)
- Figure 14. Global Targeted Drugs for Multiple Myeloma Market Share by Regions: 2020 VS 2026
- Figure 15. Global Targeted Drugs for Multiple Myeloma Market Share by Regions (2021-2026)
- Figure 16. Porter's Five Forces Analysis
- Figure 17. Global Targeted Drugs for Multiple Myeloma Market Share by Players in 2019
- Figure 18. Global Top Targeted Drugs for Multiple Myeloma Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Targeted Drugs for Multiple Myeloma as of 2019)
- Figure 19. The Top 10 and 5 Players Market Share by Targeted Drugs for Multiple Myeloma Revenue in 2019
- Figure 20. North America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 21. Europe Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 22. China Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)
- Figure 23. Japan Targeted Drugs for Multiple Myeloma Market Size YoY Growth



(2015-2020) (Million US\$)

Figure 24. Southeast Asia Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)

Figure 25. India Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)

Figure 26. Central & South America Targeted Drugs for Multiple Myeloma Market Size YoY Growth (2015-2020) (Million US\$)

Figure 27. Celgene Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 28. Celgene Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 29. Exova Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 30. Exova Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 31. Natco Pharma Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 32. Natco Pharma Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 33. Intas Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 34. Intas Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 35. Indiabulls Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 36. Indiabulls Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 37. Cipla Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 38. Cipla Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 39. Glenmark Pharmaceuticals Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 40. Glenmark Pharmaceuticals Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 41. Dr Reddy's Laboratories Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 42. Dr Reddy's Laboratories Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 43. Qilu Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 44. Qilu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 45. Chia Tai-Tianqing Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 46. Chia Tai-Tianqing Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 47. Hanson Pharm Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 48. Hanson Pharm Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 49. Meidakang Huakang Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 50. Meidakang Huakang Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 51. Shandong Kongfu Pharmaceutical Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 52. Shandong Kongfu Pharmaceutical Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 53. J&J Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 54. J&J Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 55. Takeda Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 56. Takeda Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 57. Amgen Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 58. Amgen Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 59. Bristol Myers Squibb Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 60. Bristol Myers Squibb Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 61. Abbvie Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 62. Abbvie Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 63. Seattle Genetics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 64. Seattle Genetics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 65. Karyopharm Therapeutics Total Revenue (US\$ Million): 2019 Compared with 2018

Figure 66. Karyopharm Therapeutics Revenue Growth Rate in Targeted Drugs for Multiple Myeloma Business (2015-2020)

Figure 67. Bottom-up and Top-down Approaches for This Report

Figure 68. Data Triangulation

Figure 69. Key Executives Interviewed

## I would like to order

Product name: COVID-19 Impact on Global Targeted Drugs for Multiple Myeloma Market Size, Status and Forecast 2020-2026

Product link: <https://marketpublishers.com/r/C6F41575829DEN.html>

Price: US\$ 3,900.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C6F41575829DEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

